Company intelligence / Profile preview

Script Biosciences

Philadelphia, Pennsylvania, United Statesscriptbiosciences.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Script Biosciences is developing a proprietary CRISPR-based genome editing technology called CasPlus, paired with advanced lipid nanoparticle delivery systems. Their lead preclinical program targets the mismatch repair gene MSH3 to halt progression of triplet repeat expansion diseases such as Huntington's disease and myotonic dystrophy type I. The company claims superior precision and efficiency compared to existing technologies but has not yet reported clinical results[1][2].

Therapeutic areas: Neurology
Modalities: Gene editing (CRISPR-based)mRNA/LNP delivery systems
Industry: Biotech

Drug pipeline

1 asset

CasPlus

Preclinical

Partnerships

New York University – exclusive worldwide license for CasPlus technology[2]

Beyond the preview

Go deeper on Script Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Script Biosciences.

Explore the full profile